Full-Time

Director – WW Medical Cardiovascular & Immunology

Portfolio Strategy & Business Development

Deadline 8/1/25
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Develops and delivers biopharmaceutical medicines

Compensation Overview

$207.5k - $251.4k/yr

+ Incentive Cash + Stock Opportunities

Company Historically Provides H1B Sponsorship

Princeton, NJ, USA

Hybrid

Category
📈Business & Strategy (1)
Requirements
  • Bachelor’s degree in Life Sciences, Physical sciences or relevant discipline, advanced degrees preferred (MSc, PharmD, MBA)
  • Minimum of 10 years of experience in portfolio strategy, business development, or related roles within the pharmaceutical or biotechnology industry. A solid foundation in science & medical affairs is indispensable.
  • Ability to engage in complex scientific discussions to develop/summarize clear follow-up/action plans and execute.
  • Strong understanding of the Immunology therapeutic area and market dynamics.
  • Proven track record of successfully evaluating and executing business development opportunities.
  • Excellent analytical, strategic thinking, and problem-solving skills.
  • Enterprise mindset.
  • Strong leadership and team management abilities.
  • Strong written and oral communication skills and demonstrated ability to interact directly and productively with team members and management and to manage and prioritize multiple competing priorities is also required.
  • Strong experience with building relationships, leading strategic initiatives and programs, and collaborating across divisions with people of diverse business backgrounds and cultures.
  • Comfort with ambiguity, driving change and innovation across the team.
Responsibilities
  • Effectively and efficiently collaborate with and advise leadership across the WW Medical Immunology organization to evaluate, assess, design, enhance, and develop long and short-term strategies (1-5 years).
  • Collaborate with leaders across the Immunology organization to evaluate and assess long and short-term strategies while exploring various business development opportunities as a cross-functional team.
  • Develop and implement comprehensive portfolio strategies, including business development and early asset planning for the Immunology division, aligning with overall business goals and market trends.
  • Provide medical input and perspective to identify and evaluate new opportunities, including partnerships, acquisitions, and licensing agreements, to expand the immunology portfolio.
  • Lead portfolio-level strategic initiatives such as global advisory boards and engagements with KOLs to drive insights shaping Portfolio Strategic Plans within the immunology space, identifying trends and unmet needs.
  • Gather insights to guide development decisions, target product profile creation, and commercialization strategies that best meet the needs of our patients within the immunology space.
  • Provide strategic insights and recommendations to senior leadership based on external and macro trends in the healthcare environment and the immunology space.
  • Strategically manage budgets in alignment with departmental objectives, identifying strategic activities based on business priorities, and ensuring optimal resource allocation and prioritization of projects.
  • Collaborate with R&D, Commercial, Regulatory, and other key functions to ensure seamless execution of portfolio strategies.
  • Foster a culture of collaboration and innovation across teams to drive the success of the immunology portfolio.
  • Partner with Commercial and Research & Development to integrate the medical perspective into the commercialization process and development strategy.
  • Build and maintain relationships with key internal and external stakeholders, including key opinion leaders, potential partners, industry experts, and thought leaders.
  • Represent the organization at industry conferences and meetings, connecting and collaborating in the external environment to understand evolving treatment landscapes, identify medical insights, and share findings internally with development teams.

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs that are affordable alternatives to their innovative medicines, ensuring they meet high safety and quality standards. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, along with a strong commitment to sustainability and corporate responsibility. The company's goal is to improve patient outcomes by providing effective and affordable healthcare solutions while adhering to Environmental, Social, and Governance (ESG) principles.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Simplify Jobs

Simplify's Take

What believers are saying

  • Chris Shibutani's appointment may drive strategic growth and innovation at BMS.
  • Advancements in targeted protein degradation enhance therapeutic offerings in oncology.
  • Partnership with BioNTech could provide a competitive edge against Merck's Keytruda.

What critics are saying

  • Antitrust litigation over Pomalyst could impact BMS's market position in oncology.
  • Reliance on real-world data presents challenges in data quality and implementation.
  • High costs and technical challenges in space research could affect treatment feasibility.

What makes Bristol Myers Squibb unique

  • BMS collaborates with BioNTech for next-gen cancer immunotherapy, enhancing oncology portfolio.
  • Focus on real-world data strategies could lead to faster drug market entry.
  • Developing bone disease treatments in space positions BMS as a leader in innovative research.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Company News

ISS National Lab
Jul 7th, 2025
This is Not the Time to Cut Space-enabled Medical Research

Bristol-Myers Squibb is developing novel bone disease treatments in space, and the National Stem Cell Foundation is studying 3D brain organoids derived from patients with Parkinson's disease in microgravity to observe disease progression more rapidly with the aim of identifying potential biomarkers for early diagnosis and therapeutic targets.

The Pharma Letter
Jun 26th, 2025
Bristol Myers faces new antitrust suit over multiple myeloma drug Pomalyst

Bristol Myers faces new antitrust suit over multiple myeloma drug Pomalyst.

Unlearn
Jun 24th, 2025
The Best 15 Minutes You'll Spend on Clinical Trials Today

At the 2025 "Digital Breakthrough for Pharma" Summit hosted by Bristol Myers Squibb, Unlearn's co-founder and machine learning scientist, Aaron Smith, took the stage to explain exactly how that vision is now a reality.

ROI-NJ
Jun 13th, 2025
Bristol Myers Squibb Names Shibutani As Evp, Chief Strategy Officer

Bristol Myers Squibb (BMS) this week appointed Chris Shibutani as executive vice president, chief strategy officer, effective immediately. Shibutani’s role is a new position on the BMS leadership team. The announcement was made on a LinkedIn post.Shibutani will lead the development and advancement of the company’s long-term strategic plan, collaborating across the enterprise to drive innovation and growth. He brings more than 25 years of experience in the financial services industry covering global pharmaceutical, biotechnology and medical device industries.Prior to BMS, Shibutani served as managing director in the global investment research division at Goldman Sachs. Previous roles include senior analyst positions at Hambrecht & Quist, Cowen, UBS, and J.P. Morgan.Before his career in finance, Shibutani was a physician trained in anesthesiology and critical care medicine at Massachusetts General Hospital and practiced at Memorial Sloan Kettering Cancer Center

PharmaData
Jun 13th, 2025
Bristol Myers Squibb Highlights Targeted Protein Degradation Data, Including CELMoD Agents, at EHA 2025

Bristol Myers Squibb highlights targeted protein degradation advances, including CELMoD agents and BCL6 Ligand-Directed Degrader, at EHA 2025 in Milan, Italy.